The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater.

Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one.  Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time.

With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects? 

Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.

This event will feature industry experts who will debate current developments in the area, discuss the latest innovative approaches and explore future trends.